SILO SILO PHARMA INC revenue, earnings and financials

For the quarter ended June 30, 2026, SILO PHARMA INC reported revenue of n/a, net income of −$833K and diluted EPS of −$0.76; for the fiscal year ended December 2025 revenue was $72.1K, up 0.0% on the year before.

SILO annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $72.1K, gross profit $27.8K, operating income −$4.28M, net income −$4.23M (margin -5863.5%), EPS −$0.50
• Fiscal year ended Dec 2024: revenue $72.1K, gross profit $66.3K, operating income −$4.71M, net income −$4.39M (margin -6092.6%), EPS −$1.19
• Fiscal year ended Dec 2023: revenue $72.1K, gross profit $66.3K, operating income −$3.86M, net income −$3.70M (margin -5132.6%), EPS −$1.20
• Fiscal year ended Dec 2022: revenue $72.1K, gross profit $66.3K, operating income −$3.63M, net income −$3.91M (margin -5420.9%), EPS n/a
• Fiscal year ended Dec 2021: revenue n/a, gross profit $66.3K, operating income −$2.74M, net income $3.90M (margin n/a), EPS $0.04

SILO quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$833K, EPS −$0.76
• Quarter ended Mar 31, 2026: revenue $18.0K (up 0.0% year over year), net income −$1.65M, EPS −$0.12
• Quarter ended Dec 31, 2025 (from the annual report): revenue $18.0K (up 0.0% year over year), net income −$882K, EPS $2.73
• Quarter ended Sep 30, 2025: revenue $18.0K (up 0.0% year over year), net income −$1.11M, EPS −$0.12
• Quarter ended Jun 30, 2025: revenue $18.0K (up 0.0% year over year), net income −$1.20M, EPS −$2.88
• Quarter ended Mar 31, 2025: revenue $18.0K (up 0.0% year over year), net income −$1.03M, EPS −$0.23
• Quarter ended Dec 31, 2024 (from the annual report): revenue $18.0K (up 0.0% year over year), net income −$1.73M, EPS −$0.38
• Quarter ended Sep 30, 2024: revenue $18.0K (up 0.0% year over year), net income −$929K, EPS −$0.22
• Quarter ended Jun 30, 2024: revenue $18.0K (up 0.0% year over year), net income −$932K, EPS −$0.31
• Quarter ended Mar 31, 2024: revenue $18.0K (up 0.0% year over year), net income −$802K, EPS −$0.28
• Quarter ended Dec 31, 2023 (from the annual report): revenue $18.0K, net income −$1.12M, EPS −$0.38
• Quarter ended Sep 30, 2023: revenue $18.0K (up 0.0% year over year), net income −$660K, EPS −$0.21
• Quarter ended Jun 30, 2023: revenue $18.0K (up 0.0% year over year), net income −$1.01M, EPS −$0.32
• Quarter ended Mar 31, 2023: revenue $18.0K, net income −$906K, EPS −$0.29
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$1.66M, EPS n/a
• Quarter ended Sep 30, 2022: revenue $18.0K, net income −$983K, EPS −$0.49
• Quarter ended Jun 30, 2022: revenue $18.0K (down 73.5% year over year), net income −$658K, EPS n/a
• Quarter ended Mar 31, 2022: revenue n/a, net income −$604K, EPS $0.00
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$1.09M, EPS −$3.12
• Quarter ended Sep 30, 2021: revenue n/a, net income $6.39M, EPS $3.16

SILO cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$4.66M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$3.83M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$3.22M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$3.50M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$2.28M, share buybacks n/a

SILO balance sheet

• Jun 30, 2026: cash $3.28M, total assets $5.95M, total liabilities $1.07M, shareholders' equity $4.89M
• Mar 31, 2026: cash $3.90M, total assets $7.02M, total liabilities $1.34M, shareholders' equity $5.68M
• Dec 31, 2025: cash $4.75M, total assets $7.61M, total liabilities $1.30M, shareholders' equity $6.31M
• Sep 30, 2025: cash $3.92M, total assets $6.38M, total liabilities $1.38M, shareholders' equity $5.01M
• Jun 30, 2025: cash $4.33M, total assets $6.65M, total liabilities $1.74M, shareholders' equity $4.92M
• Mar 31, 2025: cash $3.14M, total assets $5.90M, total liabilities $1.89M, shareholders' equity $4.01M
• Dec 31, 2024: cash $3.91M, total assets $7.41M, total liabilities $2.38M, shareholders' equity $5.03M
• Sep 30, 2024: cash $4.86M, total assets $8.57M, total liabilities $1.78M, shareholders' equity $6.78M

What is SILO's revenue?

SILO PHARMA INC reported $72.1K of revenue for the fiscal year ended December 2025.

Is SILO profitable?

No. SILO PHARMA INC lost $4.47M over the last four quarters.

What is SILO's EPS?

Diluted earnings per share over the last four quarters were $1.73; −$0.76 in the latest quarter.

SILO ownership and insider trades · All stocks